Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + dacarbazine
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Aldesleukin + dacarbazine is a combination regimen used primarily in the treatment of metastatic melanoma. Aldesleukin is a recombinant analog of interleukin-2 (IL-2), a cytokine that stimulates the proliferation and activation of lymphocytes to induce an adaptive immune response against tumor cells. Dacarbazine is an alkylating agent that interferes with DNA synthesis and function in rapidly dividing cancer cells. The combination leverages both immunostimulatory and cytotoxic mechanisms to enhance antitumor activity in advanced melanoma[4][1][6]. Both agents are associated with significant toxicities and are typically administered under close medical supervision.
- Other names
- recombinant human interleukin-2IL-2IL2IL 2125-L-serine-2-133-interleukin 2 (human reduced)BiocarbazineDacarbazinaDTIC
02
Targets
DNAIL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on aldesleukin + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + dacarbazine.